Kanellias Nikolaos, Ntanasis-Stathopoulos Ioannis, Gavriatopoulou Maria, Koutoulidis Vassilis, Fotiou Despina, Migkou Magdalini, Eleutherakis-Papaiakovou Evangelos, Malandrakis Panagiotis, Bagratuni Tina, Mavropoulos-Papoudas Stylianos, Roussou Maria, Kastritis Efstathios, Moulopoulos Lia A, Dimopoulos Meletios A, Terpos Evangelos
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
1st Department of Radiology, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
J Clin Med. 2022 May 30;11(11):3088. doi: 10.3390/jcm11113088.
Contemporary information is sparse on the frequency of skeletal-related events (SREs) in multiple myeloma (MM) patients at a population-based level in the era of novel agents. In this context, we conducted this single-center, prospective, observational study to determine the incidence of SREs among newly diagnosed MMs (NDMM) and to explore the possible correlations with disease characteristics, imaging finding, and patient prognosis. A total of 370 patients with available baseline MRIs were included. Among them, 208 (56%) presented with at least one SRE at diagnosis. Fractures were the most common reported SREs (48%). The incidence of SREs at diagnosis was higher in patients with osteolytic lesions, abnormal MRI pattern, hypercalcemia, and at least 60% bone marrow infiltration by plasma cells. Importantly, the patients with normal MRI pattern, who did not present with SREs at diagnosis, had statistically significant improved median OS in comparison with the patients who had abnormal MRI patterns and/or the presence of SREs at diagnosis (9.3 vs. 6.6 years, = 0.048). Our data, which represent one of a few systematic reports on the incidence and characteristics of SREs in the era of novel agents, was indicative of a high incidence of SREs at the time of MM diagnosis. Early detection of myeloma bone disease and tailored patient management are essential to optimize patient outcomes.
在新型药物时代,关于多发性骨髓瘤(MM)患者骨骼相关事件(SREs)发生率的基于人群水平的当代信息较为匮乏。在此背景下,我们开展了这项单中心、前瞻性、观察性研究,以确定新诊断MM(NDMM)患者中SREs的发生率,并探讨其与疾病特征、影像学表现和患者预后的可能相关性。共纳入370例有可用基线MRI的患者。其中,208例(56%)在诊断时出现至少一种SRE。骨折是报告最多的SREs(48%)。溶骨性病变、MRI表现异常、高钙血症以及浆细胞骨髓浸润至少60%的患者在诊断时SREs的发生率更高。重要的是,MRI表现正常且诊断时未出现SREs的患者,与MRI表现异常和/或诊断时存在SREs的患者相比,中位总生存期有统计学意义的改善(9.3年对6.6年,P = 0.048)。我们的数据是新型药物时代关于SREs发生率和特征的少数系统性报告之一,表明MM诊断时SREs的发生率较高。早期检测骨髓瘤骨病并进行针对性的患者管理对于优化患者预后至关重要。